Intelligence Β· Patent portfolio
United Therapeutics Europe Patents
Full USPTO pharma patent portfolio for United Therapeutics Europe β grant dates, expiration, and drug cross-links.
- Patents
- 3,720
- Expiring β€24m
- 234
Quick answer
United Therapeutics Europe has 3,720 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 234 expire within 24 months β use filters for patent-cliff planning.
-
US 6562589
AIB1, a novel steroid receptor co-activator
expired -
US 6562347
Chemokine-tumor antigen fusion proteins as cancer vaccines
expired -
US 6558672
Methods of making recombinant disulfide-stabilized polypeptide fragments having binding specificity
expired -
US 6558698
Microencapsulated bioactive agents and method of making
expired -
US 6558676
Parvovirus capsids
expired -
US 6559121
Vaccines for the protection of cattle from psoroptic scabies
expired -
US 6559282
Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
expired -
US 6559167
Prodrugs of proton pump inhibitors
expired -
US 6555367
Complex of biotinylated viral vector and ligand for targeted gene delivery
expired -
US 6551585
Use of tumor necrosis factor as an adjuvant
expired -
US 6552181
Basal cell carcinoma tumor supressor gene
expired -
US 6552053
Controlling attention and memory by altering neuronal carbonic anhydrase activity
expired -
US 6552006
Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
expired -
US 6551599
Monoclonal antibodies against campylobacter jejuni and campylobacter coli outer membrane antigens
expired -
US 6548068
Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
expired -
US 6548055
Immunologic enhancement with intermittent interleukin-2 therapy
expired -
US 6545142
Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
expired -
US 6541230
Detoxification with sponges or foams containing plurality of enzymes and encapsulated indicator
expired -
US 6541483
Acridone-derived compounds useful as antineoplastic and antiretroviral agents
expired -
US 6541199
Identification of a new ehrlichia species from a patient suffering from ehrlichiosis
expired -
US 6537557
Attenuated dengue-4 virus vaccine
expired -
US 6537560
Melanoma antigens and their use in diagnostic and therapeutic methods
expired -
US 6534626
Chemokine variants
expired -
US 6531131
Conjugate vaccine for Neisseria meningitidis
expired -
US 6528065
Attenuated dengue-3 virus vaccine
expired -
US 6528097
Sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
expired -
US 6524590
Identification of a new ehrlichia species from a patient suffering from ehrlichiosis
expired -
US 6521635
Inhibition of MXR transport by acridine derivatives
expired -
US 6521212
Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
expired -
US 6521229
41 kDa Cryptosporidium parvum oocyst wall protein
expired -
US 6518061
IL-13 receptor specific chimeric proteins and uses thereof
expired -
US 6517842
Marburg virus vaccines
expired -
US 6514501
Recombinant vaccine against dengue virus
expired -
US 6511667
Attenuated dengue-2 virus vaccine
expired -
US 6511991
Nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same
expired -
US 6509344
Indenoisoquinolines as antineoplastic agents
expired -
US 6506885
Monoclonal antibodies to the drug tilmicosin and a method for detecting the same
expired -
US 6500433
Polypeptide fragments capable of competition with Streptococcus mutans antigen I/II
expired -
US 6500859
Method for treating atherosclerosis or restenosis using microtubule stabilizing agent
expired -
US 6497884
Chimeric vaccine against tick-borne encephalitis virus
expired -
US 6495143
Botulinum neurotoxin vaccine
expired -
US 6495145
LktA deletion mutant of P. haemolytica
expired -
US 6492166
Use of constitutive transport elements for host range control
expired -
US 6491908
Selective elimination of T cells that recognize specific preselected targets
expired -
US 6492165
Retrovirus isolated from humans
expired -
US 6482415
Expression and refolding of truncated recombinant major outer membrane protein antigen (r56) of Orientia tsutsugamushi and its use in antibody based detection assays and vaccines
expired -
US 6479465
Methods of treating colitis using STAT-4 anti-sense oligonucleotides
expired -
US 6479286
Methods and compositions for making dendritic cells from expanded populations of monocytes and for activating T cells
expired
Frequently asked questions
How many patents does United Therapeutics Europe have?
3,720 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do United Therapeutics Europe patents expire?
234 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory